Respiratory Medicine
Volume 101, Issue 10 , Pages 2199-2206 , October 2007

Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis

  • Grethe Neumann Andersen

      Affiliations

    • Department of Rheumatology, University Hospital of Umeå, Umeå, Sweden
    • ,
  • Kenneth Nilsson

      Affiliations

    • Department of Respiratory Medicine and Allergy, University Hospital of Umeå, Umeå, Sweden
    • Contribution equal to first authorship.
    • ,
  • Jamshid Pourazar

      Affiliations

    • Department of Respiratory Medicine and Allergy, University Hospital of Umeå, Umeå, Sweden
    • ,
  • Tillie-Louise Hackett

      Affiliations

    • Division of Cell Science, School of Biological Sciences, University of Southampton, Southampton, UK
    • ,
  • Elsadig Kazzam

      Affiliations

    • Department of Cardiology, University Hospital of Umeå, Umeå, Sweden
    • Department of Cardiology, Eskilstuna Hospital, Eskilstuna, Sweden
    • ,
  • Anders Blomberg

      Affiliations

    • Department of Respiratory Medicine and Allergy, University Hospital of Umeå, Umeå, Sweden
    • ,
  • Anders Waldenström

      Affiliations

    • Department of Cardiology, Eskilstuna Hospital, Eskilstuna, Sweden
    • ,
  • Jane Warner

      Affiliations

    • Division of Cell Science, School of Biological Sciences, University of Southampton, Southampton, UK
    • ,
  • Solbritt Rantapää-Dahlqvist

      Affiliations

    • Department of Rheumatology, University Hospital of Umeå, Umeå, Sweden
    • ,
  • Lucia Mincheva-Nilsson

      Affiliations

    • Department of Clinical Immunology, University Hospital of Umeå, Umeå, Sweden
    • ,
  • Thomas Sandström

      Affiliations

    • Department of Respiratory Medicine and Allergy, University Hospital of Umeå, Umeå, Sweden
    • Corresponding Author InformationCorresponding author. Fax: +4690141369.

Received 1 December 2006 ,Accepted 22 April 2007.

References 

  1. D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428–440
  2. Steen VD, Conte C, Owens G, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283–1289
  3. Medsger TA, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971;75:69–76
  4. Devenyi K, Czirjak L. High resolution computed tomography for the evaluation of lung involvement in 101 patients with scleroderma. Clin Rheumatol. 1995;14:633–640
  5. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–1586
  6. Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47:738–742
  7. Crestani B, Seta N, Palazzo E, Rolland C, Venembre P, Dehoux M, et al. Interleukin-8 and neutrophils in systemic sclerosis with lung involvement. Am J Respir Crit Care Med. 1994;150:1363–1367
  8. Chanez P, Lacoste J-Y, Guillot B, Giron J, Barneon G, Enander I, et al. Mast cells’ contribution to the fibrosing alveolitis of the scleroderma lung. Am Rev Respir Dis. 1993;147:1497–1502
  9. Nagase H. Matrix metalloproteinases. In:  Hooper NM editors. Zinc metalloproteinases in health and disease. London: Taylor & Francis; 1996;p. 153–204
  10. Corbel M, Theret N, Caulet-Maugendre S, Germain N, Lagente V, Clement B, et al. Repeated endotoxin exposure induces interstitial fibrosis associated with enhanced gelatinase (MMP-2 and MMP-9) activity. Inflamm Res. 2001;50:129–135
  11. Suga M, Iyonaga K, Okamoto T, Gushima Y, Miyakawa H, Akaike T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2000;162:1949–1956
  12. Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Resp Med. 2003;97:634–639
  13. Finlay GA, Russell KJ, McMahon KJ, D`arcy EM, Masterson JB, FitzGerald MX, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax. 1997;52:502–506
  14. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 2000;117:684–694
  15. Russell REK, Culpitt SV, DeMatos C, Donelly L, Smith M, Wiggins J, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2002;26:602–609
  16. Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer J-M. Matrix metalloproteinases and TIMP an acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:346–352
  17. Torii K, Iida K-I, Miyazaki Y, Saga S, Kondoh Y, Taniguchi H, et al. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155:43–46
  18. Mautino G, Henriquet C, Jaffuel D, Bousquet J, Capony F. Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. Am J Respir Crit Care Med. 1999;160:324–330
  19. Cataldo DD, Gueders M, Munaut C, Rocks N, Bartsch P, Foidart J-M, et al. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases mRNA transcripts in the bronchial secretions of asthmatics. Lab Invest. 2004;84:418–424
  20. Cowland JB, Borregaard N. The individual regulation of granule protein mRNA during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukocyte Biol. 1999;66:989–995
  21. Schwingschackl A, Duszyk M, Brown N, Moqbel R. Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha. J Allergy Clin Immunol. 1999;104:983–989
  22. Masure S, Proost P, van Damme J, Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem. 1991;198:391–398
  23. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol. 2001;167:4008–4016
  24. Weeks BS, Schnaper HW, Handy M, Holloway E, Kleinman HK. Human T lymphocytes synthesise the 92kDa type IV collagenase (gelatinase B). J Cell Physiol. 1993;157:644–649
  25. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysisn) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992;267:21712–21719
  26. Frank BT, Rossall JC, Caughey GH, Fang KC. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase. J Immunol. 2001;166:2783–2792
  27. Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol. 1997;108:281–284
  28. Southcott AM, Jones KP, Li D, Majumdar S, Cambrey AD, Pantelidis P, et al. Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med. 1995;151:1604–1612
  29. Silver RM, Metcalf JF, Stanley JH, LeRoy EC. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum. 1984;27:1254–1262
  30. Gustafsson R, Fredens K, Nettelbladt O, Hällgren R. Eosinophil activation in systemic sclerosis. Arthritis Rheum. 1991;34:414–422
  31. Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–590
  32. LeRoy EC, Black C, Fleishmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205
  33. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. 1989;16:328–334
  34. Blomberg A, Krishna MT, Bocchino V, Biscione GL, Shute JK, Kelly FJ, et al. The inflammatory effects of 2ppm NO2 on the airways of healthy subjects. Am J Respir Crit Care Med. 1997;156:418–424
  35. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997;40:743–751
  36. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol. 2001;24:591–598
  37. Steen VD, Graham G, Conte C, Owens G, Medsger TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992;35:765–770
  38. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986;29:515–524
  39. Dell’aica I, Niero R, Piazza F, Cabrelle A, Sartor L, Colalto C, et al. Hyperforin blocks neutrophil activation of MMP-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis. J Pharmacol Exp Ther, 2007, February 8 [Epub ahead of print].
  40. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000;96:2673–2681
  41. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1beta by matrix metalloproteinases: a novel caspase-1 independent pathway of IL-1beta processing. J Immunol. 1998;161:3340–3346
  42. Van den Steen PE, Proost P, Grillet B, Brand DD, Kang AH, van Damme J, et al. Cleavage of denatured natural collagen type II by neutrophil collagenase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J. 2002;16:379–389
  43. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, Van den Oord J, et al. Resistance of young gelatinase-B resistant mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest. 1999;104:1507–1515
  44. Corbel M, Caulet-Maugendre S, Germain N, Molet S, Lagente V, Boichot E. Inhibition of bleomycin-induced pulmonary fibrosis by the matrix metalloproteinase inhibitor batimastat. J Pathol. 2001;193:538–545
  45. Brown PD. Ongoing trials with metalloproteinase inhibitors. Exp Opin Drugs. 2000;9:2167–2177

PII: S0954-6111(07)00184-9

doi: 10.1016/j.rmed.2007.04.019

Respiratory Medicine
Volume 101, Issue 10 , Pages 2199-2206 , October 2007

Article Tools

* Image Usage & Resolution